Trial Profile
A Randomized open label study of the effect of first line combination treatment with Avastin (bevacizumab) plus paclitaxel and gemcitabine Compared With Avastin (bevacizumab) plus paclitaxel on objective response rate in patients with Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms BEGETAX
- Sponsors Roche
- 01 Feb 2014 New trial record